LENZ Therapeutics (NASDAQ:LENZ) Now Covered by Raymond James

Raymond James assumed coverage on shares of LENZ Therapeutics (NASDAQ:LENZ) in a research report sent to investors on Friday morning, MarketBeat.com reports. The firm issued an outperform rating and a $37.00 price target on the stock.

LENZ has been the topic of several other research reports. Piper Sandler reiterated an overweight rating and issued a $36.00 price objective on shares of LENZ Therapeutics in a research note on Thursday, August 15th. HC Wainwright began coverage on shares of LENZ Therapeutics in a research note on Monday, August 12th. They issued a buy rating and a $38.00 price target on the stock. Finally, William Blair upgraded LENZ Therapeutics to a strong-buy rating in a report on Friday, August 30th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, LENZ Therapeutics presently has a consensus rating of Buy and an average target price of $35.40.

LENZ Therapeutics Trading Down 1.2 %

Shares of LENZ stock opened at $23.74 on Friday. LENZ Therapeutics has a 1-year low of $14.07 and a 1-year high of $29.82. The company’s fifty day simple moving average is $22.93.

LENZ Therapeutics (NASDAQ:LENZ) last released its earnings results on Wednesday, August 14th. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.09. On average, equities research analysts anticipate that LENZ Therapeutics will post -2.81 EPS for the current year.

Institutional Trading of LENZ Therapeutics

Several large investors have recently made changes to their positions in the stock. RA Capital Management L.P. acquired a new stake in LENZ Therapeutics in the 1st quarter worth approximately $93,313,000. Vanguard Group Inc. acquired a new position in LENZ Therapeutics during the first quarter valued at approximately $4,621,000. Jennison Associates LLC bought a new position in shares of LENZ Therapeutics in the first quarter valued at approximately $3,009,000. Ikarian Capital LLC acquired a new stake in shares of LENZ Therapeutics in the first quarter worth $1,898,000. Finally, Wealth Enhancement Advisory Services LLC acquired a new stake in shares of LENZ Therapeutics in the second quarter worth $1,437,000. Institutional investors own 54.32% of the company’s stock.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.